Kala Pharmaceuticals Inc (KALA) - Total Liabilities
Based on the latest financial reports, Kala Pharmaceuticals Inc (KALA) has total liabilities worth $1.11 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore KALA cash flow conversion to assess how effectively this company generates cash.
Kala Pharmaceuticals Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Kala Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check Kala Pharmaceuticals Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Kala Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Kala Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Commander Resources Ltd
V:CMD
|
Canada | CA$115.83K |
|
Clean & Carbon Energy S.A.
WAR:CCE
|
Poland | zł8.32 Million |
|
Nobel29 Resources Corp
V:NBLC
|
Canada | CA$405.34K |
|
CME Group Bhd
KLSE:7018
|
Malaysia | RM53.02 Million |
|
Scisparc Ltd
NASDAQ:SPRC
|
USA | $5.22 Million |
|
Fon SE
WAR:FON
|
Poland | zł2.28 Million |
|
Scout Gaming Group AB
ST:SCOUT
|
Sweden | Skr19.67 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Kala Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see KALA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kala Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kala Pharmaceuticals Inc (2013–2024)
The table below shows the annual total liabilities of Kala Pharmaceuticals Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $43.15 Million | -10.93% |
| 2023-12-31 | $48.45 Million | -28.60% |
| 2022-12-31 | $67.85 Million | -44.67% |
| 2021-12-31 | $122.62 Million | +0.83% |
| 2020-12-31 | $121.61 Million | -2.42% |
| 2019-12-31 | $124.63 Million | +7.46% |
| 2018-12-31 | $115.98 Million | +338.42% |
| 2017-12-31 | $26.45 Million | -80.27% |
| 2016-12-31 | $134.09 Million | +841.58% |
| 2015-12-31 | $14.24 Million | +68.33% |
| 2014-12-31 | $8.46 Million | +23.14% |
| 2013-12-31 | $6.87 Million | -- |
About Kala Pharmaceuticals Inc
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more